Hims & Hers posts 49% revenue growth but margin collapse and cuts 2026 guidance
+10 new sources since this summary was written
Hims & Hers Health reported third‑quarter 2026 revenue of $890.4 million, up 49% year over year, while gross margin fell to 57% from 74% a year earlier. The company posted a GAAP loss of $0.14 per share and adjusted EBITDA of $82 million. It trimmed its full‑year revenue outlook to $3.13‑$3.15 billion and adjusted EBITDA to $257‑$277 million, and forecast Q4 revenue of $875‑$895 million.
Why it matters
The guidance reduction signals lower profitability than previously expected, which may pressure the stock price. Canaccord reiterated a Buy rating but lowered its price target to $40, reflecting the earnings miss (source 10).
Key facts
- 1Q3 2026 revenue was $890.4 million, up 49% YoY. 247wallst.com
- 2Gross margin declined to 57% from 74% YoY. 247wallst.com
- 3GAAP loss was $0.14 per share, missing the expected profit of $0.06 per share. 247wallst.com
- 4Adjusted EBITDA for the quarter was $82 million, a 9% margin. finance.yahoo.com
- 5Full‑year 2026 revenue guidance was cut to $3.13‑$3.15 billion and adjusted EBITDA to $257‑$277 million. 247wallst.com
- 6International revenue reached $233 million, a 321% increase YoY. 247wallst.com
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.